WO2010133071A1 - 一种高纯度尿促卵泡刺激素及其制备方法 - Google Patents
一种高纯度尿促卵泡刺激素及其制备方法 Download PDFInfo
- Publication number
- WO2010133071A1 WO2010133071A1 PCT/CN2009/075278 CN2009075278W WO2010133071A1 WO 2010133071 A1 WO2010133071 A1 WO 2010133071A1 CN 2009075278 W CN2009075278 W CN 2009075278W WO 2010133071 A1 WO2010133071 A1 WO 2010133071A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stimulating hormone
- follicle stimulating
- purity
- group
- fsh
- Prior art date
Links
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 title claims abstract description 113
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 title claims abstract description 113
- 229940028334 follicle stimulating hormone Drugs 0.000 title claims abstract description 113
- 238000000034 method Methods 0.000 title claims abstract description 34
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title abstract 2
- 239000004202 carbamide Substances 0.000 title abstract 2
- 239000012535 impurity Substances 0.000 claims abstract description 9
- 230000002485 urinary effect Effects 0.000 claims description 56
- 238000002360 preparation method Methods 0.000 claims description 24
- 238000001042 affinity chromatography Methods 0.000 claims description 21
- 238000005277 cation exchange chromatography Methods 0.000 claims description 21
- 238000005406 washing Methods 0.000 claims description 20
- 229920002684 Sepharose Polymers 0.000 claims description 15
- 238000004587 chromatography analysis Methods 0.000 claims description 15
- 229940088597 hormone Drugs 0.000 claims description 14
- 239000005556 hormone Substances 0.000 claims description 14
- 210000002700 urine Anatomy 0.000 claims description 14
- 238000010828 elution Methods 0.000 claims description 12
- 239000003480 eluent Substances 0.000 claims description 10
- 238000011068 loading method Methods 0.000 claims description 10
- 206010036790 Productive cough Diseases 0.000 claims description 9
- 210000003802 sputum Anatomy 0.000 claims description 9
- 208000024794 sputum Diseases 0.000 claims description 9
- 239000012539 chromatography resin Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 229920000936 Agarose Polymers 0.000 claims description 6
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 6
- 239000004005 microsphere Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 125000000542 sulfonic acid group Chemical group 0.000 claims description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims description 4
- 230000003325 follicular Effects 0.000 claims description 4
- 231100000535 infertility Toxicity 0.000 claims description 4
- 208000000509 infertility Diseases 0.000 claims description 4
- 230000036512 infertility Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000000440 bentonite Substances 0.000 claims description 3
- 229910000278 bentonite Inorganic materials 0.000 claims description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 3
- CADZRPOVAQTAME-UHFFFAOYSA-L calcium;hydroxy phosphate Chemical compound [Ca+2].OOP([O-])([O-])=O CADZRPOVAQTAME-UHFFFAOYSA-L 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 229920002401 polyacrylamide Polymers 0.000 claims description 3
- 239000010453 quartz Substances 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000007790 solid phase Substances 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 229920005654 Sephadex Polymers 0.000 claims description 2
- YKCWQPZFAFZLBI-UHFFFAOYSA-N cibacron blue Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC=C1S(O)(=O)=O YKCWQPZFAFZLBI-UHFFFAOYSA-N 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000011067 equilibration Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 150000002500 ions Chemical group 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 4
- 235000019799 monosodium phosphate Nutrition 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 229910001414 potassium ion Inorganic materials 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 4
- 229910001415 sodium ion Inorganic materials 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 3
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 108010057021 Menotropins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 238000005571 anion exchange chromatography Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229940015047 chorionic gonadotropin Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 238000007086 side reaction Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- ZDRRIRUAESZNIH-BZGUUIOASA-N (2s)-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-13-[(2s)-butan-2-yl]-10-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]- Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZDRRIRUAESZNIH-BZGUUIOASA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108010047196 Urofollitropin Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- 201000005670 Anovulation Diseases 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical group [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 231100000552 anovulation Toxicity 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006408 female gonad development Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000004334 fluoridation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Definitions
- the present invention relates to the field of protein purification and biomedicine.
- the present invention relates to a high-purity follicle stimulating hormone (FSH) and a process for the preparation thereof, and a pharmaceutical composition containing the same.
- FSH follicle stimulating hormone
- Follicle-stimulating hormone is a hormone produced by the pituitary gland, which consists of two subunits, the alpha chain and the beta chain.
- the a subunit of FSH is identical to the alpha subunit of leoninizing hormone (LH) and chorionic gonadotropin (CG), with 92 amino acids and a molecular weight of approximately 14500 D.
- LH leoninizing hormone
- CG chorionic gonadotropin
- asparagine at position 78 is an amino acid that occurs - glycosylation.
- the ⁇ subunit of FSH is composed of 111 amino acids and has a molecular weight of about 18,000 D.
- the asparagine at positions 7 and 24 is an amino acid that undergoes glycosylation.
- the ⁇ subunit of LH is composed of 121 amino acids with a molecular weight of approximately 14800 D; the ⁇ subunit of CG has 145 amino acids with a molecular weight of 22000-39000 D.
- FSH is mainly used to treat infertility and assisted reproduction in vitro.
- FSH can be extracted from the urine of menopausal women or can be prepared by DNA recombination techniques.
- the first product containing FSH is urinary gonadotropin (HMG), such as Serono's Pergonal, which is a mixture of FSH and LH in a ratio of about 1.
- HMG urinary gonadotropin
- Serono's Pergonal which is a mixture of FSH and LH in a ratio of about 1.
- Metrodin only removes LH, but still retains a lot of urine source of heteroproteins (about 90-90% of heteroproteins).
- the presence of these heterologous proteins may cause certain side effects, such as allergic reactions. Therefore, in recent years, the market is eager to develop and use high purity FSH, which is low purity.
- the FSH is further purified to remove most of the heterologous protein and obtain a high specific activity FSH, which can overcome the allergic reaction to the human body caused by a large amount of heteroprotein in common products, and because of these advantages, it can be injected subcutaneously. It is convenient for patients to use and relieve pain.
- the current preparation method of urinary FSH is mainly based on low-purity urinary follicle stimulating hormone or menopausal gonadotropin (HMG), by hydrophobic chromatography, monoclonal antibody immunochromatography and reversed phase HPLC. Purification, but the specific activity and purity of the obtained FSH is not very satisfactory, and there are occasional reports of side reactions.
- HMG menopausal gonadotropin
- the present invention aims to provide a high-purity urinary follicle stimulating hormone.
- Another object of the present invention is to provide a process for the preparation of the high-purity urinary follicle stimulating hormone. It is still another object of the present invention to provide the use of the high purity urinary follicle stimulating hormone.
- PFSH high-purity urinary follicle stimulating hormone
- the high-purity urinary follicle stimulating hormone has a purity of not less than 95 w/w% and an impurity content of not more than 5 w/ 0w/w% ⁇
- the impurity content is not less than 2. 0w / w%, its impurity content does not exceed 2. 0w / w%.
- the follicular sputum hormone is a human-derived follic sputum hormone or a variant thereof; more preferably, the follicular sputum hormone is a human urine-derived follic sputum hormone or a variant thereof.
- the low-purity urinary follicle stimulating hormone is purified by chromatography to obtain a high-purity urinary follicle stimulating hormone; the chromatogram is dye affinity chromatography.
- the chromatogram further comprises a cation exchange chromatography.
- the method includes the steps of:
- step (a) comprises the steps of:
- the dye affinity chromatography in step (b) comprises the steps of:
- the resin skeleton medium of the cation exchange chromatography comprises agarose, dextran, fiber a crosslinker of styrene and divinylbenzene, a crosslinker of acrylic acid and/or a derivative thereof.
- the resin reactive group of the cation exchange chromatography is selected from the group consisting of sulfonic acid propyl groups
- the reactive group of the chromatographic column of the cation exchange chromatography is selected from the group consisting of a sulfonic acid propyl group or a methine sulfonic acid group.
- the cation exchange chromatography resin is SP Sepharose or CM
- the dye ligand of the dye affinity chromatography resin is selected from the group consisting of Ciba Cr . nBl Ue , Orange Red, Greer
- the solid phase carrier of the dye affinity chromatography resin is selected from the group consisting of bentonite, glass microspheres, quartz microspheres, calcium hydroxyphosphate, alumina, polyacrylamide gel, starch gel, and Portuguese Glycan gel, cellulose, or agarose.
- the dye affinity chromatography resin is Blue Sepharose 6B or Blue Sepharose FF.
- step (a) or (b) is carried out 13 times.
- a pharmaceutical composition is provided, the composition comprising a treatment An effective amount of the high purity urinary follicle stimulating hormone provided by the present invention as described above, and a pharmaceutically acceptable carrier.
- the present invention provides a high-purity FSH, and a corresponding preparation method, thereby obtaining a preparation containing high-purity FSH, which can be used for subcutaneous injection, reducing the incidence of side reactions, facilitating the use and alleviation of patients. pain.
- FIG. 1 shows the FSH purity map.
- the inventors have extensively and intensively studied and surprisingly found that the currently known highest purity FSH can be obtained by cation exchange resin chromatography and dye affinity resin chromatography.
- the invention adopts urine or HMG or low-purity urinary follicle stimulating hormone as a starting material, and obtains high-purity FSH by an innovative cation exchange resin chromatography and dye affinity resin chromatography, and the purification method is simple and effective, and obtains
- the FSH has high purity and less impurities.
- the terms "follicle stimulating hormone” and "FSH” are used interchangeably and refer to a class of hormones or variants thereof for promoting sperm or follicle production, promoting ovarian development, which may be naturally preceded by the pituitary gland. Leaf secretion.
- urinary follicle stimulating hormone and “urinary FSH” are used interchangeably and refer to follic sputum hormones extracted from urine, which are derived from mammals, preferably from humans. More preferably, the urine of a menopausal woman.
- the low-purity urinary FSH used in the present invention can be obtained by any means commonly used in the art, for example, by conventional methods from the urine of menopausal women through kaolin adsorption, elution, acetone precipitation, ethanol solution extraction, ions Exchange chromatography (including cation, anion chromatography), or even hydrophobic chromatography to obtain HMG, and then obtain low-purity urine by conventional means such as hydrophobic chromatography or affinity chromatography with anti-LH antibody and/or anti-CG antibody.
- Source FSH such as the method described in CN 101307103A. .
- the specific activity of low purity urine-derived FSH is generally lower than 2000 IU/mg protein, preferably 200-500 IU/mg protein.
- the low-purity urinary FSH raw material which can be used in the present invention may be: HMG is subjected to a pre-purification step to remove LH raw materials, or is subjected to kaolin adsorption, elution, acetone precipitation, ethanol from menopausal women's urine according to a conventional extraction method.
- the raw material low purity urinary FSH is initially purified by conventional methods in the art to separate impurities other than LH.
- HMG can be obtained by conventional methods, such as kaolin adsorption, elution, acetone precipitation, ethanol solution extraction, ion exchange chromatography (including cation, anion chromatography), and even hydrophobic chromatography from the urine of menopausal women. Subsequent purification of the HMG can then be carried out by hydrophobic chromatography or removal of LH therefrom, followed by preparation as disclosed in this patent to obtain highly active FSH.
- the specific activity of the low-purity urinary FSH raw material as a starting material is below 2000 IU/mg protein, preferably 200-500 IU/mg protein.
- luteal hormone and “LH” are used interchangeably and refer to
- the high-purity urinary follicle stimulating hormone provided by the present invention has a purity of 95% and an impurity of 5%.
- the bioavailability of LH in the high purity urine-derived FSH provided by the present invention is less than 1 LH IU/100 FSH IU.
- the preparation method of the high-purity urine-derived FSH provided by the invention comprises the steps of:
- the method comprises the steps of:
- the solution 2 containing the distillate 1 is purified by dye affinity chromatography to obtain a high-purity urinary follicle stimulating hormone (pFSH).
- pFSH urinary follicle stimulating hormone
- the skeleton medium of the cation exchange chromatography column used in the preparation method of the present invention comprises a crosslinked product of agarose, dextran, cellulose, styrene, acrylic acid and/or a derivative; the cation exchange chromatography column
- the reactive group is selected from the group consisting of sulfonic acid propyl (-S0 3 H), methine sulfonate (-CH 2 S0 3 H), a carboxyl group (-C00H), a carboxymethyl group (- 0C C00H), or a phenol group (-C 6 3 ⁇ 40H), preferably selected from a sulfonic acid propyl group or a methylene sulfonic acid group
- the cation exchange chromatography column is SP Sepharose or CM Sepharose.
- the elution solution of the cation exchange chromatography used in the preparation method of the present invention is pH 2-8, and the ion concentration is 0 - 2M; the ions are selected from sodium ions and potassium ions.
- the dye ligand of the chromatographic affinity chromatography column used in the preparation method of the present invention is selected from Cibacron Blue, Orange, Red, Green;
- the solid phase carrier of the chromatographic column of the dye affinity chromatography is selected from the group consisting of bentonite and glass microspheres. , quartz microspheres, calcium hydroxyphosphate, alumina, polyacrylamide gel, starch gel, dextran gel, cellulose, or agarose;
- the chromatographic column of the dye affinity chromatography is Blue Sepharose 0 invention
- the elution solution of the dye affinity chromatography used in the preparation method is pH 6-12, and the ion concentration is 0 -
- the ions are selected from the group consisting of sodium ions and potassium ions.
- the cation exchange chromatography purification step comprises:
- the gradient elution is carried out in step (iii), and the concentration (v/v) of the first eluent is from 0 to 100% in 0.5 to 5 hours.
- the first loading solution has a salt concentration of 0 to 0.5 M, and the salt is selected from the group consisting of a hydrochloride, a phosphate, and/or an acetate; the first washing liquid or the first eluating liquid.
- the salt concentration is from 0.05 to 3 M, and the salt is selected from the group consisting of hydrochloride, phosphate, and/or acetate.
- the metal ion of the salt is selected from sodium ion or potassium ion.
- the dye affinity chromatography purification step comprises:
- the second sample solution has a salt concentration of 0 to 0.05 M, and the salt is selected from the group consisting of a hydrochloride, a phosphate, and/or an acetate; the second or second eluent.
- the salt concentration is 0.01-5M,
- the salt is selected from the group consisting of hydrochloride, phosphate, and/or acetate, and/or glycinate.
- the metal ion of the salt is selected from sodium or potassium ions.
- the invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the high purity urinary FSH prepared by the method of the invention, and a pharmaceutically acceptable carrier.
- the term “containing” or “including” includes “comprising”, “consisting essentially of”, and “consisting of”.
- the term “therapeutically effective amount” refers to an amount that is functional or active to a human and/or animal and that is acceptable to humans and/or animals.
- the term "pharmaceutically acceptable” or “food acceptable” ingredients are suitable for use in humans and/or animals without excessive adverse side effects (such as toxicity, irritability, and allergies; , that is, a substance with a reasonable benefit/risk ratio.
- the term "pharmaceutically acceptable carrier” refers to a carrier for the administration of a therapeutic agent, including various excipients and diluents.
- the term refers to pharmaceutical carriers which are not themselves essential active ingredients and which are not excessively toxic after administration. Suitable carriers are well known to those of ordinary skill in the art. A full discussion of pharmaceutically acceptable excipients can be found in Remington's Pharmaceutical Sciences, Mack Pub. Co., N.J. 1991.
- the "pharmaceutically acceptable carrier” may contain liquids such as water, saline, glycerol and ethanol.
- auxiliary substances such as fillers, disintegrants, lubricants, glidants, effervescent agents, wetting or emulsifying agents, flavoring agents, pH buffering substances and the like may also be present in these carriers.
- these materials can be formulated in a non-toxic, inert, and pharmaceutically acceptable aqueous carrier medium wherein the pH is usually from about 5 to about 8, preferably, the pH is from about 6 to about 8.
- the high purity urinary FSH in the pharmaceutical composition comprises from 0.001 to 99.9 wt% of the total weight of the composition; preferably from 0.01 to 99 wt%, more preferably 0.02, based on the total weight of the composition. - 95 wt%, more preferably 0.05 - 90 wt%.
- the balance is a pharmaceutically acceptable carrier and other additives.
- unit dosage form refers to a dosage form required to prepare a composition of the present invention for single administration for ease of administration, including but not limited to various solid agents (eg, tablets;), liquid agents, capsules. Agent, slow release agent, powder injection.
- the composition is in unit dosage form or in multiple dosage forms, and wherein the content of FSH is from 0.001 to 2000 mg per dose, preferably from 0.003 to 500 mg per dose, more preferably from 0.005 to 50 mg per dose.
- one to six doses of the composition of the invention are administered per day, preferably one to three doses; most preferably, the daily administration of the agent The amount is 1 dose.
- the effective dose of FSH used may vary with the severity of the subject to be administered or treated.
- the specific situation is determined by the individual circumstances of the subject (e.g., subject weight, age, physical condition, desired effect); this is within the range that the skilled physician or dietitian can judge.
- the pharmaceutical composition of the present invention may be in the form of a solid (e.g., granules, tablets, lyophilized powder, suppository, capsule, sublingual tablet) or a liquid (e.g., oral solution, aqueous injection; or other suitable shape).
- a solid e.g., granules, tablets, lyophilized powder, suppository, capsule, sublingual tablet
- a liquid e.g., oral solution, aqueous injection; or other suitable shape.
- a high-purity urinary FSH is provided, which can be applied to subcutaneous injection;
- a high-purity purification method of urinary FSH is provided, which is simple and effective, and is suitable for industrialization.
- the invention is further illustrated below in conjunction with specific embodiments. It is to be understood that the examples are not intended to limit the scope of the invention.
- the experimental methods in which the specific conditions are not indicated in the following examples are usually carried out according to conventional conditions or according to the conditions recommended by the manufacturer. All percentages, ratios, ratios, or parts are by weight unless otherwise indicated.
- the unit of weight percent by volume in the present invention is well known to those skilled in the art and, for example, refers to the weight of the solute in a 100 ml solution.
- Sample preparation Take the sample and dissolve it to 500 IU/mL with mobile phase.
- a low-purity urinary follicle stimulating hormone (purchased from Shanghai Tianwei Biopharmaceutical Co., Ltd.) was used as a starting material, wherein the bioavailability of FSH was 315 IU/mg, and the bioavailability of LH was 3 IU/mg.
- FSH biopotency FSH specific activity (IU/mg LH biopotency
- NaOH was adjusted to pH 6. 5 ⁇ 0.2, and sterile filtration was carried out using a 0.22 ⁇ m filter. Then, it was added to the above FSH solution, and the volume was adjusted to 750 mL with pyrogen-free water for injection, and the mixture was mixed.
- each bottle contained 75 IU of FSH and 10 mg of lactose.
- the above is only the preferred embodiment of the present invention, and is not intended to limit the scope of the technical scope of the present invention.
- the technical content of the present invention is broadly defined in the scope of the claims of the application, any technical entity completed by others. The method or method, if it is identical to the scope of the claims, or equivalents, is considered to be within the scope of the claims.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
Description
一种高纯度尿促卵泡刺激素及其制备方法 技术领域
本发明涉及蛋白质纯化和生物医药领域。 具体而言, 本发明涉及高纯度 的卵泡剌激素(FSH)及其制备方法, 以及含有它的药物组合物。 背景技术
卵泡剌激素(Follicle- stimulating hormone, 简称 FSH)是由垂体产生 的激素, 它由 α链和 β链两个亚基组成。 FSH 的 a亚基与黄体生成激素 (leuteinizing hormone , 简称 LH) 禾口 绒毛膜促性腺素 (chorionic gonadotropin, 简称 CG)的 α亚基完全相同, 具有 92个氨基酸, 分子量约为 14500 D, 第 52和 78位置上的天冬酰胺是发生 -糖基化的氨基酸。
FSH的 β亚基由 111个氨基酸组成, 分子量约为 18000 D, 其中第 7和 24位置上的天冬酰胺是发生 -糖基化的氨基酸。 而 LH的 β亚基由 121个氨 基酸组成, 分子量约为 14800 D; CG 的 β亚基则有 145 个氨基酸, 分子量 22000-39000 D。
临床上 FSH主要用于治疗不育症以及体外的辅助生殖。 FSH可以从绝经 期妇女的尿液中提取出来, 也可通过 DNA重组技术而制备。
含有 FSH的第一代产品是尿促性素(HMG), 如 Serono公司的 Pergonal, 它是 FSH与 LH比例约为 1 的混合物。 但是, 对于体内有较多量的 LH而不需 加用外源性 LH的患者, LH水平过高会影响卵泡的正常发育, 不合时机的抑 制减数分裂抑制因子会导致卵子的老化, 从而降低受精和着床的机会。 因此 对这部分患者而言, 更适合于使用纯 FSH制剂。 另一方面, 过多的 LH容易 导致多囊卵巢综合症(Polycystic Ovarian Syndrome, P00S), 研究表明, LH过多对生殖功能有不利的作用, 如引起月经稀发、 无排卵、 不孕及流产。 因此对 P00S患者用纯 FSH治疗比 HMG更为安全, 可减少卵巢过度剌激综合 ¾E (Ovarian Hypers timulat ion Syndrome , 0HSS)危险。 Serono 公司推出的 Metrodin就是一种含有极少量 LH的 FSH制剂, 适合 P00S患者的治疗。
但是, Metrodin仅仅是去除了 LH, 但还是保留了很多尿源的杂蛋白 (杂 蛋白约占 80— 90%) , 这些杂蛋白的存在可能会导致一定的副作用, 如过敏 反应。 因此近年来市场上正倾向于开发和使用高纯度的 FSH, 它是将低纯度
的 FSH进行进一步的纯化, 去除绝大部分杂蛋白, 获得高比活的 FSH, 它可 以克服普通产品中因大量杂蛋白而造成的对人体的过敏反应, 并且由于这些 优点使得它可以采用皮下注射, 方便患者的使用, 减轻痛苦。
目前的尿源 FSH的制备方法主要是以低纯度尿促卵泡剌激素或绝经期促 性腺素 (HMG ) 为起始原料, 通过疏水色谱, 或单克隆抗体免疫层析法以及 反相 HPLC法来纯化, 但获得的 FSH 的比活和纯度还不是十分理想, 偶有产 生副反应的报到。
因此, 本领域迫切需要开发出一种高纯度的 FSH, 以及相应的制备方法, 并由此获得含高纯度 FSH的制剂, 可以使用于皮下注射, 减少副反应的发生 几率, 方便患者的使用、 减轻痛苦。 发明内容
本发明旨在提供一种高纯度尿促卵泡剌激素。
本发明的另一个目的是提供所述高纯度尿促卵泡剌激素的制备方法。 本发明的再一个目的是提供所述高纯度尿促卵泡剌激素的用途。 在本发明的第一方面, 提供了一种高纯度尿促卵泡剌激素 (PFSH ) , 所述 的高纯度尿促卵泡剌激素的纯度不低于 95w/w%,其杂质含量不超过 5w/w% ; 较 佳地, 其纯度不低于 98. 0w/w%,其杂质含量不超过 2. 0w/w%。
在另一优选例中, 卵泡剌激素是人来源的卵泡剌激素或其变体; 更佳地, 卵泡剌激素是人尿来源的卵泡剌激素或其变体。 在本发明的第二方面, 提供了一种如上所述的本发明提供的高纯度尿促卵 泡剌激素的制备方法, 所述的方法包括步骤:
将低纯度尿促卵泡剌激素经过色谱纯化, 得到高纯度尿促卵泡剌激素; 所述的色谱是染料亲和色谱。
在另一优选例中, 所述的色谱还包括阳离子交换色谱。
在另一优选例中, 所述的方法包括步骤:
( a )将含有低纯度尿促卵泡剌激素的溶液 1经过阳离子交换色谱纯化, 得 到馏出物 1 ; 和
( b )将含有馏出物 1的溶液 2经过染料亲和色谱纯化, 得到高纯度尿促卵
泡剌激素。
在另一优选例中, 步骤 (a)中的阳离子交换色谱包括步骤:
(i)用 pH4 7含有低纯度尿促卵泡剌激素的第一上样液进行上样,所述第一 上样液中低纯度尿促卵泡剌激素的浓度为 0.1— 10w/v% (g/ml) ;
(ii)用 pH4 6的第一洗涤液进行洗涤; 和
(iii)用 pH4 6的第一洗涤液和 pH4 6的第一洗脱液进行洗脱, 得到馏出 物 1。
在另一优选例中, 步骤 (b)中的染料亲和色谱包括步骤:
(i')用 pH5— 7含有馏出物 1的第二上样液进行上样; 所述第二上样液中馏 出物 1的浓度为 0.05-5w/v% (g/ml)
(ii')用 pH6— 11的第二洗涤液进行洗涤; 和
(iii 用 PH6— 11的第二洗脱液进行洗脱, 得到高纯度尿促卵泡剌激素。 在另一优选例中, 所述阳离子交换色谱的树脂骨架介质包括琼脂糖, 葡聚 糖, 纤维素, 苯乙烯和二乙烯基苯的交联物, 丙烯酸和 /或其衍生物的交联物。
在另一优选例中, 所述的阳离子交换色谱的树脂活性基团选自磺酸丙基
(- S03H)、 次甲基磺酸基(- C S03H)、 羧基(- C00H)、 羧甲基(- 0C C00H)、 或苯 酚基 (-C6H50H) 。
在另一优选例中, 所述的阳离子交换色谱的色谱柱的活性基团选自磺酸丙 基、 或次甲基磺酸基。
在另一优选例中, 所述的阳离子交换色谱的树脂是 SP Sepharose 或 CM
Sepharose。
在另一优选例中, 所述染料亲和色谱的树脂的染料配基选自 CibaCr。nBlUe、 Orange Red、 Greer
在另一优选例中, 所述染料亲和色谱的树脂的固相载体选自皂土、 玻璃微 球、 石英微球、 羟磷酸钙、 氧化铝、 聚丙烯酰胺凝胶、 淀粉凝胶、 葡聚糖凝 胶、 纤维素、 或琼脂糖。
在另一优选例中, 所述染料亲和色谱的树脂是 Blue Sepharose 6B或 Blue Sepharose FF。
在另一优选例中, 步骤 (a) 或 (b) 进行 1 3次。 在本发明的第三方面, 提供了一种药物组合物, 所述的组合物中含有治疗
有效量的如上所述的本发明提供的高纯度尿促卵泡剌激素、 和药学上可接受的 载体。 在本发明的第四方面, 提供了一种如上所述的本发明提供的高纯度尿促 卵泡剌激素在制备治疗不育综合症的药物中的用途。 据此, 本发明提供了一种高纯度的 FSH, 以及相应的制备方法, 并由此 获得含高纯度 FSH的制剂, 可以使用于皮下注射, 减少副反应的发生几率, 方便患者的使用、 减轻痛苦。 附图说明
图 1显示了 FSH纯度图谱。 具体实施方式
发明人经过广泛而深入的研究, 惊奇地发现通过阳离子交换树脂色谱和 染料亲和树脂色谱可以获得目前已知的最高纯度的 FSH。
具体而言, 本发明是以尿或 HMG或低纯度尿促卵泡剌激素为起始原料, 通过创新的阳离子交换树脂色谱和染料亲和树脂色谱, 得到高纯度的 FSH, 纯化方法简单有效, 获得的 FSH纯度高、 杂质少。 如本发明所用, 术语 "卵泡剌激素" 和 " FSH " 可互换使用, 指一类用 于促进精子或卵泡产生、 促进卵巢发育的激素或其变体, 其可在天然情况下 由垂体前叶分泌。
如本文所用, "尿促卵泡剌激素" 和 "尿源性 FSH " 可互换使用, 是指 从尿液中提取得到的卵泡剌激素, 所述尿液来自于哺乳动物,优选来自于人, 更佳地是绝经期妇女的尿液。
本发明中所用的原料低纯度尿源性 FSH 可采用本领域常用的任何方式 获得, 例如可以用传统方法从绝经期妇女尿液中通过高岭土吸附、 洗脱, 丙 酮沉淀, 乙醇溶液抽提, 离子交换层析色谱 (包括阳离子、 阴离子色谱) , 甚至疏水色谱得到 HMG, 再将 HMG通过疏水层析、 或者通过抗 LH抗体和 / 或抗 CG 抗体的亲和层析等常规手段来获得低纯度尿源性 FSH, 如 CN 101307103A 所描述的方法。 。 低纯度尿源性 FSH 的比活一般低于
2000IU/mg蛋白, 优选 200— 500IU/mg蛋白。
可用于本发明中的低纯度尿源性 FSH原料可为: 将 HMG经过预纯化步 骤去除 LH的原料,或按传统提取方法从绝经期妇女尿液中通过高岭土吸附、 洗脱, 丙酮沉淀, 乙醇溶液抽提, 离子交换层析色谱 (包括阳离子、 阴离子 色谱) , 然后再通过疏水层析、 或者通过抗 LH抗体和 /或抗 CG抗体的亲和 层析等常规方法来获得的基本上只含 FSH和其它非 LH的杂蛋白的原料。
优选在采用本发明的方法纯化低纯度尿源性 FSH前,采用本领域常规方 法对原料低纯度尿源性 FSH进行初步纯化, 以分离除 LH以外的其它杂质。
HMG 可以按传统的方法获得, 如从绝经期妇女尿液中通过高岭土吸附、 洗脱, 丙酮沉淀, 乙醇溶液抽提, 离子交换层析色谱 (包括阳离子、 阴离子 色谱) , 甚至疏水色谱。 然后将 HMG进行后续的纯化, 可以用疏水色谱或去 除其中的 LH, 然后按本专利公开的方法进行制备从而获得高活性的 FSH。
作为起始原料的低纯度尿源性 FSH原料的比活在 2000IU/mg蛋白以下, 优选 200— 500IU/mg蛋白。
如本文所用, 术语 "黄体生成激素" 和 " LH " 可互换使用, 指在含有
FSH的原料制备或获取过程中掺杂于其中的与天然 LH具有相同或相似结构 和功能的激素。 本发明提供的高纯度尿促卵泡剌激素的纯度 95%, 杂质 5%。 本发明提供 的高纯度尿源性 FSH中 LH的生物效价小于 1 LH IU/100 FSH IU。
本发明提供的高纯度尿源性 FSH的制备方法包括步骤:
将低纯度尿源性卵泡剌激素或绝经期促性腺素 (HMG) 经过色谱纯化, 得到 高纯度尿源性 FSH; 所述的色谱是阳离子交换色谱和染料亲和色谱。
优选地, 所述的方法包括步骤:
( 1 )将含有低纯度 FSH的溶液 1经过阳离子交换色谱纯化, 得到馏出物 1 ; 禾口
( 2 )将含有馏出物 1的溶液 2经过染料亲和色谱纯化, 得到高纯度尿促卵 泡剌激素 ( pFSH ) 。
本发明制备方法中使用的阳离子交换色谱的色谱柱的骨架介质包括琼脂 糖、 葡聚糖、 纤维素、 苯乙烯、 丙烯酸和 /或衍生物的交联物; 所述的阳离子 交换色谱的色谱柱的活性基团选自磺酸丙基(-S03H)、 次甲基磺酸基
(- CH2S03H)、 羧基(- C00H)、 羧甲基(- 0C C00H)、 或苯酚基 (- C6¾0H) , 较佳 地选自磺酸丙基、 或次甲基磺酸基; 所述的阳离子交换色谱的色谱柱是 SP Sepharose或 CM Sepharose。
本发明制备方法中使用的阳离子交换色谱的洗脱溶液 pH2-8, 离子浓度 0— 2M; 所述离子选自钠离子、 钾离子。
本发明制备方法中使用的染料亲和色谱的色谱柱的染料配基选自 Cibacron Blue, Orange, Red, Green; 所述染料亲和色谱的色谱柱的固相载体选自皂土、 玻璃微球、 石英微球、 羟磷酸钙、 氧化铝、 聚丙烯酰胺凝胶、 淀粉凝胶、 葡 聚糖凝胶、纤维素、或琼脂糖;所述染料亲和色谱的色谱柱是 Blue Sepharose0 本发明制备方法中使用的染料亲和色谱的洗脱溶液 pH6-12, 离子浓度 0—
4M; 所述离子选自钠离子、 钾离子。
在本发明的一个优选例中, 所述阳离子交换色谱纯化步骤包括:
(i)用 pH4— 7 含有低纯度尿促卵泡剌激素的第一上样液进行上样,所述 第一上样液中低纯度尿促卵泡剌激素的浓度为 0.1— 10w/v% (g/ml) , 优选 2.0-4.0w/v% (g/ml) ;
(ii)用 pH4— 6的第一洗涤液进行洗涤; 和
(iii)用 pH4— 6 的第一洗涤液和 pH4— 6 的第一洗脱液进行洗脱, 得到 馏出物 1。
更佳地, 步骤(iii)中进行梯度洗脱, 在 0.5 至 5 小时内, 第一洗脱液 的浓度 (v/v) 从 0至 100%。
所述的第一上样液的盐浓度为 0— 0.5M, 所述的盐选自盐酸盐、 磷酸盐、 和 /或醋酸盐; 所述的第一洗涤液或第一洗脱液的盐浓度为 0.05— 3M, 所述 的盐选自盐酸盐、 磷酸盐、 和 /或醋酸盐。 所述盐的金属离子选自钠离子或 钾离子。
在本发明的一个优选例中, 所述染料亲和色谱纯化步骤包括:
(i')用 pH5— 7含有馏出物 1 的第二上样液进行上样;所述第二上样液中 馏出物 1 的浓度为 0.05— 5w/v% (g/ml)
(ii')用 pH8— 11 的第二洗涤液进行洗涤; 和
(iii')用 pH8— 11 的第二洗脱液进行洗脱,得到高比活尿促卵泡剌激素。 所述的第二上样液的盐浓度为 0— 0.05M,所述的盐选自盐酸盐、磷酸盐、 和 /或醋酸盐; 所述的第二洗涤液或第二洗脱液的盐浓度为 0.01— 5M, 所述
的盐选自盐酸盐、 磷酸盐、 和 /或醋酸盐、 和 /或甘氨酸盐。 所述盐的金属离 子选自钠离子或钾离子。 本发明还提供了一种药物组合物, 所述的药物组合物含有治疗有效量的 用本发明方法制备的高纯度尿源性 FSH, 以及药学上可接受的载体。
如本文所用, 术语 "含有"或 "包括"包括了 "包含" 、 "基本上由…… 构成" 、 和 "由……构成" 。 如本文所用, 术语 "治疗有效量" 是指可对人 和 /或动物产生功能或活性的且可被人和 /或动物所接受的量。
如本文所用, 术语 "药学上可接受的" 或 "食品学上可接受的" 的成分 是适用于人和 /或动物而无过度不良副反应 (;如毒性、 剌激和变态反应;)的, 即 有合理的效益 /风险比的物质。
如本文所用, 术语 "药学上可接受的载体" 指用于治疗剂给药的载体, 包括各种赋形剂和稀释剂。 该术语指这样一些药剂载体: 它们本身并不是必 要的活性成分, 且施用后没有过分的毒性。 合适的载体是本领域普通技术人 员所熟知的。 在 《雷明顿药物科学》 (Remington ' s Pharmaceutical Sciences , Mack Pub. Co. , N.J. 1991)中可找到关于药学上可接受的赋形剂的充分讨论。
所述的 "药学上可接受的载体"可含有液体, 如水、 盐水、 甘油和乙醇。 另外, 这些载体中还可能存在辅助性的物质, 如填充剂、 崩解剂、 润滑剂、 助流剂、 泡腾剂、 润湿剂或乳化剂、 矫味剂、 pH缓冲物质等。 通常, 可将这 些物质配制于无毒的、 惰性的和药学上可接受的水性载体介质中, 其中 pH 通常约为 5-8, 较佳地, pH约为 6-8。
在本发明的优选实施方式中,所述药物组合物中的高纯度尿源性 FSH占 组合物总重量的 0.001— 99.9wt%; 优选为组合物总重量的 0.01— 99wt%, 较 优选为 0.02— 95wt%, 更优选 0.05— 90wt%。 余量为药学上可接受的载体以 及其它添加剂等物质。
如本文所用, 术语 "单位剂型" 是指为了服用方便, 将本发明的组合物 制备成单次施用所需的剂型, 包括但不限于各种固体剂 (如片剂;)、 液体剂、 胶囊剂、 缓释剂、 粉针剂。 在本发明的另一优选实施方式中, 所述组合物为 单位剂型或多剂型, 且其中 FSH 的含量为 0.001-2000mg/剂, 优选 0.003-500mg/剂, 更优选 0.005-50mg/剂。 在本发明的另一个优选例中, 每天 施用 1一 6剂本发明的组合物, 优选施用 1一 3剂; 最优选的, 每天施用的剂
量为 1剂。
应理解, 所用 FSH的有效剂量可随待施用或治疗的对象的严重程度而变 化。 具体情况根据对象的个体情况 (例如对象体重、 年龄、 身体状况、 所需达 到的效果;)来决定, 这在熟练医师或营养师可以判断的范围内。
本发明的药物组合物, 可以为固态 (如颗粒剂、 片剂、 冻干粉、 栓剂、 胶 囊、 舌下含片)或液态 (如口服液、 水针剂;)或其它合适的形状。 本发明提到的上述特征, 或实施例提到的特征可以任意组合。 本案说明书 所揭示的所有特征可与任何组合物形式并用, 说明书中所揭示的各个特征, 可 以任何可提供相同、 均等或相似目的的替代性特征取代。 因此除有特别说明, 所揭示的特征仅为均等或相似特征的一般性例子。 本发明的主要优点在于:
1、 提供了一种高纯度的尿源性 FSH, 可应用于皮下注射;
2、 提供了一种高纯度的尿源性 FSH 的纯化方法, 方法简单有效, 适合 产业化。 下面结合具体实施例, 进一步阐述本发明。 应理解, 这些实施例仅用于 说明本发明而不用于限制本发明的范围。 下列实施例中未注明具体条件的实 验方法, 通常按照常规条件或按照制造厂商所建议的条件。 除非另外说明, 否则所有的百分数、 比率、 比例、 或份数按重量计。
本发明中的重量体积百分比中的单位是本领域技术人员所熟知的, 例如 是指在 100毫升的溶液中溶质的重量。
除非另行定义, 文中所使用的所有专业与科学用语与本领域熟练人员所 熟悉的意义相同。 此外, 任何与所记载内容相似或均等的方法及材料皆可应 用于本发明方法中。 文中所述的较佳实施方法与材料仅作示范之用。 本发明涉及的生物效价和纯度的测定方法:
生物效价
FSH、 LH的生物效价测定方法按中国药典 2005版附录 XI I M、 XI I N的 方法检验。
纯度
色谱柱: Superdex75 10/300 GL
流动相: 乙腈: 0. 2M磷酸钠溶液 pH7. 0 = 200 : 1000
样品配制: 取样品用流动相溶解至 500 IU/mL
进样量: 100 μ L
检测波长: 215 nm
运行时间: 60 min 实施例 1
制备高纯度尿促卵泡刺激素 I
将低纯度尿促卵泡剌激素(购自上海天伟生物制药有限公司)用作起始 原料, 其中 FSH的生物效价为 315 IU/mg, LH的生物效价为 3 IU/mg。
将 10g上述低纯度尿促卵泡剌激素用 300mL平衡液(0. 03M磷酸二氢钠, pH5 ) 溶解, 然后上至 250mL CM-Sepharose层析柱 (Amersham提供) , 此柱 事先已用相同的平衡液平衡好。 上样结束后用洗涤液 (0. 1M 醋酸钠, pH5 ) 洗涤 10倍柱体积, 然后用洗涤液和洗脱液 (0. 1M醋酸钠 + lM NaCl, pH5 ) 进 行 0— 100%线性梯度洗脱, 用紫外检测器监测 280nm处, 分布收集各馏出峰, 检测其 FSH免疫效价, 合并有效成份约 0. 4 L, 加入预冷的无水乙醇沉淀过 夜, 次日离心收集沉淀, 用无水乙醇脱水, 真空干燥得到 1. 8克干品。
将 1. 8 g上述干品用 200mL平衡液 (0. 01M磷酸二氢钠, pH6. 5 ) 溶解, 然后上至 300mL Blue Sepharose FF层析柱 (Amersham提供) 上, 上样结束 后用平衡液洗涤 5倍柱体积, 然后用 0. 05M甘氨酸缓冲液 (pHIO ) 洗涤 5倍 柱体积, 再用 0. 05M甘氨酸、 0. 4M NaCl缓冲液 (pH9 ) 洗涤 8倍柱体积, 最 后用洗脱液 (0. 05M 甘氨酸、 2. 5M NaCl , pH9 ) 洗脱, 分布收集各馏出峰, 检测其 FSH免疫效价, 合并有效成份约 2L, 用 1万分子量膜超滤浓缩后, 加 入预冷的无水乙醇, 离心收集沉淀, 用无水乙醇脱水, 真空干燥得 266mg干 燥品 I, 即高纯度尿促卵泡剌激素 I。 FSH纯度图谱见附图 1。
表 1 所得 F燥品的生物效价及比活测定结果
FSH生物效价 FSH比活(IU/mg LH生物效价
FSH纯度 (IU/mg) 蛋白) (IU/mg)
纯化后的干燥品 <1LH III /100FSH
9209 9352
I III
上述结果表明: 采用本发明的方法进行纯化, 可以获得很高纯度的 FSH。 实施例 2
制备高纯度尿促卵泡刺激素 II
将 5g低纯度尿促卵泡剌激素 (起始原料同实施例 1) 用 150mL平衡液 (0.03M磷酸二氢钠, ρΗ4·8) 溶解, 然后上至 130mL SP- Sepharose层析柱 (Amersham提供) , 此柱事先已用相同的平衡液平衡好。 上样结束后用洗涤 液 (0.1M醋酸钠, pH4.8) 洗涤 10倍柱体积, 然后用洗涤液和洗脱液 (0.1M 醋酸钠 + 1M NaCl, pH5) 进行 0— 100%线性梯度洗脱 (洗脱液的体积比浓度, 在 2小时内) , 用紫外检测器监测 280nm处, 分布收集各馏出峰, 检测其 FSH 免疫效价, 合并有效成份约 0.2 L, 加入预冷的无水乙醇沉淀过夜, 次日离 心收集沉淀, 用无水乙醇脱水, 真空干燥得到 0.93克干品。
将 0.93g上述干品用 lOOmL平衡液 (0.01M磷酸二氢钠, pH6.5) 溶解, 然后上至 200mL Blue Sepharose 6B层析柱 (Amersham提供) 上, 上样结束 后用平衡液洗涤 5倍柱体积, 然后用 0.05M甘氨酸缓冲液 (pHIO) 洗涤 5倍 柱体积, 再用 0.05M甘氨酸、 0.4M NaCl缓冲液 (pH9) 洗涤 10倍柱体积, 最后用洗脱液 (0.05M甘氨酸、 2.5MNaCl, pH9) 洗脱, 分布收集各馏出峰, 检测其 FSH免疫效价, 合并有效成份约 1.5L, 用 1万分子量膜超滤浓缩后, 加入预冷的无水乙醇, 离心收集沉淀, 用无水乙醇脱水, 真空干燥得 120mg 干燥品 II, 即高纯度尿促卵泡剌激素 II。
高纯度尿促卵泡刺激素冻干针剂
用于制造 1000瓶 FSH冻干针剂, 且每瓶含 75 IU FSH的生产的典型例子 如下:
计算出 FSH的所需量(以生物效价为单位), 按此量称取实施例 1 中 FSH 干燥品 I, 溶解于 20mL注射用无热原水中, 如果需要的话, 用 HC1或 NaOH 调节 pH 6. 5 ± 0. 2, 然后用 0. 22 μ ηι过滤器进行无菌过滤。
将 10g乳糖溶解于 200mL注射用无热原水中, 如果需要的话, 用 HC1或
NaOH调节 pH 6. 5 ± 0. 2, 用 0. 22 μ m过滤器进行无菌过滤。 然后加入到上述 FSH溶液中, 用注射用无热原水定容至 750mL, 混匀。
将上述溶液分装入安瓿瓶中, 每瓶 0. 75mL, 进行冷冻干燥。
所得到的安瓿瓶中, 每瓶含 75 IU FSH和 10mg乳糖。 以上所述仅为本发明的较佳实施例而已, 并非用以限定本发明的实质技 术内容范围, 本发明的实质技术内容是广义地定义于申请的权利要求范围 中, 任何他人完成的技术实体或方法, 若是与申请的权利要求范围所定义的 完全相同, 也或是一种等效的变更, 均将被视为涵盖于该权利要求范围之中。
Claims
1.一种高纯度尿促卵泡剌激素(pFSH ),其特征在于,其纯度不低于 95w/w%, 其杂质含量不超过 5w/w% ; 优选纯度不低于 98. 0w/w%,其杂质含量不超过 2. 0w/w%。
2.如权利要求 1 所述的高纯度尿促卵泡剌激素, 其特征在于, 卵泡剌激素 是人来源的卵泡剌激素或其变体; 更佳地, 卵泡剌激素是人尿来源的卵泡剌 激素或其变体。
3.一种如权利要求 1 2任一所述的高纯度尿促卵泡剌激素的制备方法, 其 特征在于, 所述的方法包括步骤:
将低纯度尿促卵泡剌激素经过色谱纯化, 得到高纯度尿促卵泡剌激素; 所述的色谱是染料亲和色谱。
4. 如权利要求 3所述的制备方法, 其特征在于, 所述的色谱还包括阳离子 交换色谱。
5.如权利要求 3或 4所述的制备方法, 其特征在于, 所述的方法包括步骤:
( a )将含有低纯度尿促卵泡剌激素的溶液 1经过阳离子交换色谱纯化, 得 到馏出物 1 ; 和
(b )将含有馏出物 1的溶液 2经过染料亲和色谱纯化, 得到高纯度尿促卵 泡剌激素。
6. 如权利要求 5所述的方法, 其特征在于, 步骤 (a)中的阳离子交换色谱 包括步骤:
(i)用 pH4 7含有低纯度尿促卵泡剌激素的第一上样液进行上样,所述第一 上样液中低纯度尿促卵泡剌激素的浓度为 0. 1— 10w/v% ( g/ml ) ;
(i i)用 pH4 6的第一洗涤液进行洗涤; 和
(i i i)用 pH4 6的第一洗涤液和 pH4 6的第一洗脱液进行洗脱, 得到馏出 物 1。
7. 如权利要求 5所述的方法, 其特征在于, 步骤 (b)中的染料亲和色谱包 括步骤:
(i')用 pH5— 7含有馏出物 1的第二上样液进行上样; 所述第二上样液中馏 出物 1的浓度为 0. 05 - 5w/v% ( g/ml )
(i i')用 pH6— 11的第二洗涤液进行洗涤; 和
(i i i 用 PH6— 11的第二洗脱液进行洗脱, 得到高纯度尿促卵泡剌激素。
8.如权利要求 3 7任一项所述的方法, 其特征在于, 所述阳离子交换色谱 的树脂骨架介质包括琼脂糖, 葡聚糖, 纤维素, 苯乙烯和二乙烯基苯的交联 物, 丙烯酸和 /或其衍生物的交联物。
9.如权利要求 3 7任一项所述的方法, 其特征在于, 所述的阳离子交换色 谱的树脂活性基团选自磺酸丙基(-S03H)、 次甲基磺酸基(-CH2S03H)、 羧基 (- C00H)、 羧甲基(- 0C C00H)、 或苯酚基 ( -C6H50H) 。
10.如权利要求 9所述的制备方法, 其特征在于, 所述的阳离子交换色谱的 色谱柱的活性基团选自磺酸丙基、 或次甲基磺酸基。
11.如权利要求 3— 7任一项所述的方法, 其特征在于, 所述的阳离子交换 色谱的树脂是 SP Sepharose或 CM Sepharose。
12.如权利要求 3— 7任一项所述的方法, 其特征在于, 所述染料亲和色谱 的树脂的染料配基选自 Cibacron Blue, Orange, Red, Green。
13.如权利要求 3— 7任一项所述的方法, 其特征在于, 所述染料亲和色谱 的树脂的固相载体选自皂土、 玻璃微球、 石英微球、 羟磷酸钙、 氧化铝、 聚 丙烯酰胺凝胶、 淀粉凝胶、 葡聚糖凝胶、 纤维素、 或琼脂糖。
14.如权利要求 3— 7任一项所述的方法, 其特征在于, 所述染料亲和色谱 的树月旨是 Blue Sepharose 6B或 Blue Sepharose FF。
15.如权利要求 5所述的制备方法, 其特征在于, 步骤 (a ) 或 (b ) 进行 1
- 3次。
16. 一种药物组合物, 其特征在于, 所述的组合物中含有治疗有效量的如 权利要求 1 2任一所述的高纯度尿促卵泡剌激素、 和药学上可接受的载体。
17 . 一种如权利要求 1 2 任一所述的高纯度尿促卵泡剌激素在制备治 疗不育综合症的药物中的用途。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100514837A CN101555279B (zh) | 2009-05-19 | 2009-05-19 | 一种高纯度尿促卵泡刺激素及其制备方法 |
CN200910051483.7 | 2009-05-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010133071A1 true WO2010133071A1 (zh) | 2010-11-25 |
Family
ID=41173577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2009/075278 WO2010133071A1 (zh) | 2009-05-19 | 2009-12-03 | 一种高纯度尿促卵泡刺激素及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN101555279B (zh) |
WO (1) | WO2010133071A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114671944A (zh) * | 2022-04-29 | 2022-06-28 | 江苏尤里卡生物科技有限公司 | 一种人绒毛膜促性腺激素纯化方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101555279B (zh) * | 2009-05-19 | 2013-03-27 | 上海天伟生物制药有限公司 | 一种高纯度尿促卵泡刺激素及其制备方法 |
CN101928342B (zh) * | 2009-06-18 | 2013-05-08 | 上海天伟生物制药有限公司 | 一种高纯度绝经期促性腺素及其制备方法和用途 |
CN101869827A (zh) * | 2010-04-30 | 2010-10-27 | 北京九州泰康生物科技有限责任公司 | 一种新型亲和介质的制备方法及其应用 |
CN102464713A (zh) * | 2010-12-21 | 2012-05-23 | 上海丽珠制药有限公司 | 一种卵泡刺激素的制备方法 |
CN102924588A (zh) * | 2012-10-26 | 2013-02-13 | 日照新康生物科技有限公司 | 一种高比活尿促卵泡素的制备方法 |
CN114835796A (zh) * | 2022-05-05 | 2022-08-02 | 江苏尤里卡生物科技有限公司 | 一种促性腺激素纯化方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1587276A (zh) * | 2004-07-23 | 2005-03-02 | 南昌市万华生化制品有限公司 | 高纯度尿卵泡刺激素的纯化及生产工艺 |
US7022822B1 (en) * | 1999-04-16 | 2006-04-04 | Instituto Massone S.A. | Highly purified gonadotropin compositions and process for preparing them |
CN1890265A (zh) * | 2003-12-22 | 2007-01-03 | 阿雷斯贸易股份有限公司 | Fsh的纯化方法 |
CN101087805A (zh) * | 2004-11-09 | 2007-12-12 | 阿雷斯贸易股份有限公司 | Fsh的纯化方法 |
CN101519445A (zh) * | 2009-04-08 | 2009-09-02 | 上海天伟生物制药有限公司 | 一种高比活尿促卵泡刺激素及其制备方法 |
CN101555279A (zh) * | 2009-05-19 | 2009-10-14 | 上海天伟生物制药有限公司 | 一种高纯度尿促卵泡刺激素及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6414123B1 (en) * | 1997-10-21 | 2002-07-02 | Vitro Diagnostics, Inc. | Method for purifying FSH |
CN1189475C (zh) * | 1999-01-26 | 2005-02-16 | Ibsa生物化学研究股份有限公司 | 分离和纯化促卵泡激素和黄体生成激素的方法 |
CN1195069C (zh) * | 2002-11-28 | 2005-03-30 | 南京医科大学 | 人卵泡刺激素β亚基单克隆抗体的制备方法 |
CN1803838A (zh) * | 2006-01-23 | 2006-07-19 | 南京医科大学 | 卵泡刺激素受体特异结合区域多肽、表达载体及其制备方法和在制药中的应用 |
CN101307103B (zh) * | 2007-09-11 | 2012-01-04 | 上海天伟生物制药有限公司 | 一种卵泡刺激素的纯化方法 |
-
2009
- 2009-05-19 CN CN2009100514837A patent/CN101555279B/zh active Active
- 2009-12-03 WO PCT/CN2009/075278 patent/WO2010133071A1/zh active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7022822B1 (en) * | 1999-04-16 | 2006-04-04 | Instituto Massone S.A. | Highly purified gonadotropin compositions and process for preparing them |
CN1890265A (zh) * | 2003-12-22 | 2007-01-03 | 阿雷斯贸易股份有限公司 | Fsh的纯化方法 |
CN1587276A (zh) * | 2004-07-23 | 2005-03-02 | 南昌市万华生化制品有限公司 | 高纯度尿卵泡刺激素的纯化及生产工艺 |
CN101087805A (zh) * | 2004-11-09 | 2007-12-12 | 阿雷斯贸易股份有限公司 | Fsh的纯化方法 |
CN101519445A (zh) * | 2009-04-08 | 2009-09-02 | 上海天伟生物制药有限公司 | 一种高比活尿促卵泡刺激素及其制备方法 |
CN101555279A (zh) * | 2009-05-19 | 2009-10-14 | 上海天伟生物制药有限公司 | 一种高纯度尿促卵泡刺激素及其制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114671944A (zh) * | 2022-04-29 | 2022-06-28 | 江苏尤里卡生物科技有限公司 | 一种人绒毛膜促性腺激素纯化方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101555279B (zh) | 2013-03-27 |
CN101555279A (zh) | 2009-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010133071A1 (zh) | 一种高纯度尿促卵泡刺激素及其制备方法 | |
KR0156565B1 (ko) | 뇨난포 자극호르몬 | |
US20060079460A1 (en) | Purified LH | |
US20070299001A1 (en) | PURIFIED hCG | |
WO2010115318A1 (zh) | 一种高比活尿促卵泡刺激素及其制备方法 | |
US5990288A (en) | Method for purifying FSH | |
JP4574865B2 (ja) | 高度に精製されたゴナドトロピン組成物およびそれらの製造方法 | |
Free et al. | Separation and properties of multiple components of bovine growth hormone | |
WO2010111845A1 (zh) | 一种高比活绝经期促性腺素及其制备方法和用途 | |
JP2579771B2 (ja) | 胸腺抽出物、その製造方法及びそれを含む薬剤組成物 | |
CA2113868A1 (en) | Ultra-pure human interleukin-6 | |
CN109879938B (zh) | 一种醋酸加尼瑞克的制备方法 | |
KR20120042844A (ko) | 고순도 인간 폐경기 성선자극호르몬, 이의 제조방법 및 용도 | |
JP2000302690A (ja) | 不妊治療剤 | |
IE83494B1 (en) | Essentially pure human parathyroid hormone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09844823 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09844823 Country of ref document: EP Kind code of ref document: A1 |